PauseRX review

PauseRX makes disclosures this category usually refuses. Its FAQ names Rush Pharmacy as the pharmacy it works with and Beluga Health as the physician network; PauseRX, Inc. is named as the corporation; and the FDA's compounded-medication language is reproduced verbatim rather than paraphrased into something softer. Its peptide shelf is priced and specific, with sermorelin injection from $349 a month and NAD⁺ injection from $249 on their own product pages — though its category pages print those two figures the other way round, so confirm which is yours. Then read the ordering terms, because they are strict: its FAQ says an order cannot be changed or canceled once submitted, and medication cannot be returned or exchanged. Know that before you click.

PauseRX is a direct-to-consumer telehealth platform whose product menu is unusually granular for its size: sermorelin injection and sermorelin troches under Performance; NAD⁺ injection and NAD⁺ troches under Longevity; glutathione injection and glutathione nasal spray under Antioxidant; a GHK-Cu cream under Skin; TriMix, PT-141, sildenafil and tadalafil under Sexual Health; hormone therapy for women, including estradiol, under Hormones; and compounded semaglutide, compounded tirzepatide, MIC+B12 and consultations for brand Wegovy, Zepbound and Foundayo under Weight Loss. Its men's testosterone line — cypionate, creams, a spray and enclomiphene — is listed but marked "coming soon". Despite the brand name it is not positioned as menopause-specific care.

Asynchronous by default, with the platform noting that some states may require a video or chat element and that a provider reviews orders within about 24 hours. What distinguishes it is the transparency stack. Its FAQ names Rush Pharmacy, with a website and email, as its pharmacy, and Beluga Health as the physician-led virtual care platform handling prescriptions; its returns address is a Rush Pharmacy address in Oviedo, Florida; and PauseRX, Inc. is the named legal entity. Those can be checked independently, which is a materially different position from a site that says only "a licensed US pharmacy". Billing is at ship rather than at order, and its FAQ says monthly refills are not debited automatically — you are notified, a provider reviews, and you choose to pay. Set against that: no state-by-state coverage list is published despite a nationwide claim, no medical director is named as an individual, the LegitScript seal carries no certification number printed on the page, and no corporate physical address is given. And the cancellation terms are severe in their own words — orders begin processing immediately and cannot be changed or canceled once submitted, with medication non-returnable and non-exchangeable.

Published per molecule, with one wrinkle. On the product pages, sermorelin injection is stated as starting at $349 a month and NAD⁺ injection as starting at $249 a month. The category pages disagree: the Performance page lists sermorelin at $249 beside sermorelin troches at $249, and the Longevity page lists NAD⁺ at $349 beside NAD⁺ troches at $249 — the injection figures appear swapped. GHK-Cu cream starts at $199 and PT-141 at $299 a month. Read "starting at" as literally as it is written: these are entry figures for a personalized prescription, so ask whether the number moves once a provider sets your dose, and ask what the monthly shipment contains, because neither vial size nor concentration is stated beside the price. On the weight-loss side, compounded semaglutide is flat at $199 across all doses and compounded tirzepatide starts at $249 — genuinely good structure, since a dose increase does not raise the bill — but those are GLP-1 numbers and neither is a peptide or NAD⁺ price. Insurance is not accepted and HSA/FSA eligibility is not confirmed on the site.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. PauseRX reproduces the disclosure verbatim — compounded medications are patient-specific, compounded in a licensed 503(A) compounding pharmacy, are not FDA-approved and have not been reviewed by the FDA for safety, efficacy or quality — which is more precise than most competitors manage, and it names its pharmacy, so the chain is traceable. On evidence, the menu spans the full range. Sermorelin is a GHRH analog stimulating your own pituitary, preserving the feedback loop that exogenous growth hormone overrides: a real mechanism whose long-term human outcome data thins out badly beyond short-term IGF-1 changes, and the troche route has less pharmacokinetic support than the injection. Injected, intranasal and sublingual NAD⁺ have no controlled human outcome trials; oral NR and NMN raise a blood level. Glutathione and GHK-Cu have essentially no controlled human outcome data. PT-141 is the exception in the other direction — bremelanotide is an FDA-approved drug for one narrow indication, generalized hypoactive sexual desire disorder in premenopausal women, so a compounded version prescribed to anyone else is off-label use of an approved molecule. Individual results vary.